Industry News
GTG expands US reach for BREVAGen
Genetic Technologies (ASX:GTG) signed a deal with a US health insurance network, more than doubling the ‘in-network’ reach for its BREVAGen breast cancer risk screening tool. [ + ]
Agreement signed between Garvan, Cancer Therapeutics CRC and SYNkinase
The development of a new research tool for proteomics and chemical biology is set to move forward. [ + ]
Mesoblast publishes results of AMI trial
Mesoblast’s (ASX:MSB) adult MPCs were able to improve cardiac function in an animal model of acute myocardial infarction, a study shows. [ + ]
Bionomics and CTx hit cancer treatment milestone
Bionomics (ASX:BNO) and CTx said a compound from their VEGFR3 inhibitor program was able to suppress cancer progression in an animal model of melanoma. [ + ]
Pig poo problem solved
An Australian-led project to turn 1.4 million tonnes of Chinese pig poo into alternative energy and fertiliser has been hailed in a national science award. [ + ]
Grow your own electricity
Researchers have engineered a strain of electricity-producing bacteria that can grow using hydrogen gas as its sole electron donor and carbon dioxide as its sole source of carbon. [ + ]
UQ scientist wins top prize for battling rheumatoid arthritis and tuberculosis
A Queensland medical researcher who is on the trail of genetic markers for rheumatoid arthritis and tuberculosis has won the state’s top science prize. [ + ]
UWA forms spin-out company to develop nanoparticle cancer drugs
The University of Western Australia (UWA) and Yuuwa Capital LP have set up a new spin-out company, Eridan Technology, to commercialise nanoparticle technology for drug delivery applications. [ + ]
New spin-out company to develop nanoparticle drugs
A new spin-out company has been set up by the University of Western Australia to commercialise nanoparticle drugs for biomedical applications. [ + ]
A simple step from ocean to land
The shape change required for animals to make the major evolutionary transition from ocean to land appears to have been simpler than previously thought. [ + ]
Revised code to benefit ASX-listed life science companies
The Minister for Technology, the Hon Gordon Rich-Phillips, yesterday joined forces with the Australian Securities Exchange (ASX) and Australia’s biotechnology industry association, AusBiotech, to launch a revised edition of the industry code of best practice that will support capital formation by ASX-listed life science companies. [ + ]
REVA appoints new managing director
Michel Vanbrabant will joint REVA Medical (ASX:RVA) as managing director to help the company prepare its EU market strategy for bioresorbable coronary scaffold ReZolve2. [ + ]
pSivida posts $2.8m loss for Q3
pSivida (ASX:PVA) says its net loss grew slightly in Q3, as it awaits revenue and royalty payments from partner Alimera for the Iluvien insert. [ + ]
Partnership in sleep-disordered breathing
The University of Sydney and ResMed have created a new partnership that will support research into sleep disorders. [ + ]
Brain rewiring
A collaborative research project has advanced our understanding of brain plasticity. [ + ]
